{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:44:27Z","timestamp":1787787867194,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"China Scholarship Council\u2013University of Bristol joint-funded PhD Scholarship","award":["201906250207"],"award-info":[{"award-number":["201906250207"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac steatosis is an early yet overlooked feature of diabetic cardiomyopathy. There is no available therapy to treat this condition. Tyrosine kinase inhibitors (TKIs) are used as first or second-line therapy in different types of cancer. In cancer patients with diabetes mellitus, TKIs reportedly improved glycemic control, allowing insulin discontinuation. They also reduced liver steatosis in a murine model of non-alcoholic fatty liver disease. The present study aimed to determine the therapeutic effect of the second-generation TKI Dasatinib on lipid accumulation and cardiac function in obese, type 2 diabetic mice. We also assessed if the drug impacts extra-cardiac fat tissue depots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two studies on 21-week-old male obese leptin receptor mutant BKS.Cg-+Leprdb\/+Leprdb\/OlaHsd (db\/db) mice compared the effect of Dasatinib (5\u00a0mg\/kg) and vehicle (10% DMSO\u2009+\u200990% PEG-300) given via gavage once every three days for a week or once every week for four weeks. Functional and volumetric indices were studied using echocardiography. Post-mortem analyses included the assessment of fat deposits and fibrosis using histology, and senescence using immunohistochemistry and flow cytometry. The anti-adipogenic action of Dasatinib was investigated on human bone marrow (BM)-derived mesenchymal stem cells (MSCs). Unpaired parametric or non-parametric tests were used to compare two and multiple groups as appropriate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dasatinib reduced steatosis and fibrosis in the heart of diabetic mice. The drug also reduced BM adiposity but did not affect other fat depots. These structural changes were associated with improved diastolic indexes, specifically the E\/A ratio and non-flow time. Moreover, Dasatinib-treated mice had lower levels of p16 in the heart compared with vehicle-treated controls, suggesting an inhibitory impact of the drug on the senescence signalling pathway. In vitro, Dasatinib inhibited human BM-MSC viability and adipogenesis commitment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that Dasatinib opposes heart and BM adiposity and cardiac fibrosis. In the heart, this was associated with favourable functional consequences, namely improvement in an index of diastolic function. Repurposing TKI for cardiac benefit could address the unmet need of diabetic cardiac steatosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-023-01955-9","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T17:02:06Z","timestamp":1692291726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice"],"prefix":"10.1186","volume":"22","author":[{"given":"Yue","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria V","family":"Alvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita C","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poppy J","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashton","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"issue":"1","key":"1955_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1955_CR2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1161\/CIRCRESAHA.120.315899","volume":"126","author":"LR Peterson","year":"2020","unstructured":"Peterson LR, Gropler RJ. Metabolic and molecular imaging of the Diabetic Cardiomyopathy. Circ Res. 2020;126(11):1628\u201345.","journal-title":"Circ Res"},{"key":"1955_CR3","doi-asserted-by":"crossref","unstructured":"Mordi IR. Non-invasive imaging in Diabetic Cardiomyopathy. J Cardiovasc Dev Dis 2019, 6(2).","DOI":"10.3390\/jcdd6020018"},{"issue":"5","key":"1955_CR4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(5):602\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1955_CR5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","volume":"118","author":"PC Schulze","year":"2016","unstructured":"Schulze PC, Drosatos K, Goldberg IJ. Lipid use and misuse by the heart. Circ Res. 2016;118(11):1736\u201351.","journal-title":"Circ Res"},{"issue":"6","key":"1955_CR6","doi-asserted-by":"publisher","first-page":"e000433","DOI":"10.1161\/JAHA.113.000433","volume":"2","author":"M Bayeva","year":"2013","unstructured":"Bayeva M, Sawicki KT, Ardehali H. Taking diabetes to heart\u2013deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc. 2013;2(6):e000433.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"1955_CR7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","volume":"116","author":"JM McGavock","year":"2007","unstructured":"McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170\u20135.","journal-title":"Circulation"},{"issue":"10","key":"1955_CR8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","volume":"49","author":"TS Park","year":"2008","unstructured":"Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008;49(10):2101\u201312.","journal-title":"J Lipid Res"},{"key":"1955_CR9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3389\/fendo.2020.00652","volume":"11","author":"A Kovilakath","year":"2020","unstructured":"Kovilakath A, Jamil M, Cowart LA. Sphingolipids in the heart: from cradle to Grave. Front Endocrinol (Lausanne). 2020;11:652.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1955_CR10","doi-asserted-by":"crossref","unstructured":"Faulkner A, Dang Z, Avolio E, Thomas AC, Batstone T, Lloyd GR, Weber RJ, Najdekr L, Jankevics A, Dunn WB et al. Multi-Omics Analysis of Diabetic Heart Disease in the db\/db model reveals potential targets for treatment by a Longevity-Associated Gene. Cells 2020, 9(5).","DOI":"10.3390\/cells9051283"},{"issue":"4","key":"1955_CR11","doi-asserted-by":"crossref","first-page":"H339","DOI":"10.1152\/ajpheart.00742.2014","volume":"308","author":"DJ Glenn","year":"2015","unstructured":"Glenn DJ, Cardema MC, Ni W, Zhang Y, Yeghiazarians Y, Grapov D, Fiehn O, Gardner DG. Cardiac steatosis potentiates angiotensin II effects in the heart. Am J Physiol Heart Circ Physiol. 2015;308(4):H339\u2013350.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"1955_CR12","doi-asserted-by":"crossref","first-page":"e007372","DOI":"10.1161\/CIRCIMAGING.117.007372","volume":"11","author":"ACT Ng","year":"2018","unstructured":"Ng ACT, Strudwick M, van der Geest RJ, Ng ACC, Gillinder L, Goo SY, Cowin G, Delgado V, Wang WYS, Bax JJ. Impact of Epicardial Adipose tissue, left ventricular myocardial Fat Content, and interstitial fibrosis on myocardial contractile function. Circ Cardiovasc Imaging. 2018;11(8):e007372.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"1955_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1574886316666210112153429","volume":"16","author":"JM Pappachan","year":"2021","unstructured":"Pappachan JM. Efficacy and Cardiovascular Safety of Antidiabetic Medications. Curr Drug Saf. 2021;16(2):115\u201321.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"1955_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12933-020-01188-0","volume":"20","author":"L Wang","year":"2021","unstructured":"Wang L, Cai Y, Jian L, Cheung CW, Zhang L, Xia Z. Impact of peroxisome proliferator-activated receptor-alpha on diabetic cardiomyopathy. Cardiovasc Diabetol. 2021;20(1):2.","journal-title":"Cardiovasc Diabetol"},{"key":"1955_CR15","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3389\/fimmu.2018.03133","volume":"9","author":"K Guo","year":"2018","unstructured":"Guo K, Bu X, Yang C, Cao X, Bian H, Zhu Q, Zhu J, Zhang D. Treatment Effects of the second-generation tyrosine kinase inhibitor Dasatinib on Autoimmune Arthritis. Front Immunol. 2018;9:3133.","journal-title":"Front Immunol"},{"issue":"3","key":"1955_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/sjmms.sjmms_492_21","volume":"10","author":"M Althubiti","year":"2022","unstructured":"Althubiti M. Tyrosine kinase targeting: a potential therapeutic strategy for diabetes. Saudi J Med Med Sci. 2022;10(3):183\u201391.","journal-title":"Saudi J Med Med Sci"},{"issue":"11","key":"1955_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","volume":"26","author":"A Fountas","year":"2015","unstructured":"Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a Novel Treatment paradigm? Trends Endocrinol Metab. 2015;26(11):643\u201356.","journal-title":"Trends Endocrinol Metab"},{"key":"1955_CR18","doi-asserted-by":"crossref","unstructured":"Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(8):502\u2013514.","DOI":"10.2139\/ssrn.3773520"},{"key":"1955_CR19","doi-asserted-by":"crossref","unstructured":"Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015;9:773\u2013779.","DOI":"10.2147\/DDDT.S80207"},{"key":"1955_CR20","doi-asserted-by":"crossref","unstructured":"Islam MT, Tuday E, Allen S, Kim J, Trott DW, Holland WL, Donato AJ, Lesniewski LA. Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging Cell. 2023;22(2):e13767.","DOI":"10.1111\/acel.13767"},{"key":"1955_CR21","doi-asserted-by":"crossref","unstructured":"Murakami T, Inagaki N, Kondoh H. Cellular senescence in Diabetes mellitus: distinct senotherapeutic strategies for adipose tissue and pancreatic beta cells. Front Endocrinol (Lausanne). 2022;13:869414.","DOI":"10.3389\/fendo.2022.869414"},{"key":"1955_CR22","doi-asserted-by":"crossref","unstructured":"Elsayed HRH, El-Nablaway M, Othman BH, Abdalla AM, El Nashar EM, Abd-Elmonem MM, El-Gamal R. Can dasatinib ameliorate the hepatic changes, induced by long term western diet, in mice? Ann Anat. 2021;234:151626.","DOI":"10.1016\/j.aanat.2020.151626"},{"key":"1955_CR23","doi-asserted-by":"crossref","unstructured":"Duggan BM, Foley KP, Henriksbo BD, Cavallari JF, Tamrakar AK, Schertzer JD. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia. Sci Rep. 2017;7(1):1578.","DOI":"10.1038\/s41598-017-01822-0"},{"issue":"7","key":"1955_CR24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00125-019-4865-6","volume":"62","author":"G Mangialardi","year":"2019","unstructured":"Mangialardi G, Ferland-McCollough D, Maselli D, Santopaolo M, Cordaro A, Spinetti G, Sambataro M, Sullivan N, Blom A, Madeddu P. Bone marrow pericyte dysfunction in individuals with type 2 diabetes. Diabetologia. 2019;62(7):1275\u201390.","journal-title":"Diabetologia"},{"issue":"7","key":"1955_CR25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db18-0044","volume":"67","author":"D Ferland-McCollough","year":"2018","unstructured":"Ferland-McCollough D, Maselli D, Spinetti G, Sambataro M, Sullivan N, Blom A, Madeddu P. MCP-1 Feedback Loop between Adipocytes and mesenchymal stromal cells causes Fat Accumulation and contributes to hematopoietic stem cell rarefaction in the bone marrow of patients with diabetes. Diabetes. 2018;67(7):1380\u201394.","journal-title":"Diabetes"},{"issue":"4","key":"1955_CR26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"1","key":"1955_CR27","doi-asserted-by":"crossref","first-page":"15701","DOI":"10.1038\/s41598-020-72924-5","volume":"10","author":"I Cuijpers","year":"2020","unstructured":"Cuijpers I, Carai P, Mendes-Ferreira P, Simmonds SJ, Mulder P, Miranda-Silva D, De Giorgio D, Pokreisz P, Heymans S, Jones EAV. The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Sci Rep. 2020;10(1):15701.","journal-title":"Sci Rep"},{"key":"1955_CR28","doi-asserted-by":"crossref","unstructured":"Chong M, Yin T, Chen R, Xiang H, Yuan L, Ding Y, Pan CC, Tang Z, Alexander PB, Li QJ et al. CD36 initiates the secretory phenotype during the establishment of cellular senescence. EMBO Rep 2018, 19(6).","DOI":"10.15252\/embr.201745274"},{"issue":"1","key":"1955_CR29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00395-012-0313-1","volume":"108","author":"GP Fadini","year":"2013","unstructured":"Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G, Agostini C, Cappellari R, et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol. 2013;108(1):313.","journal-title":"Basic Res Cardiol"},{"key":"1955_CR30","doi-asserted-by":"crossref","unstructured":"Samarakoon R, Higgins SP, Higgins CE, Higgins PJ. The TGF-beta1\/p53\/PAI-1 Signaling Axis in Vascular Senescence: role of Caveolin-1. Biomolecules 2019, 9(8).","DOI":"10.3390\/biom9080341"},{"issue":"4","key":"1955_CR31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cellsig.2005.08.009","volume":"18","author":"GY Carmen","year":"2006","unstructured":"Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal. 2006;18(4):401\u20138.","journal-title":"Cell Signal"},{"issue":"9","key":"1955_CR32","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s40618-021-01501-y","volume":"44","author":"ML Morieri","year":"2021","unstructured":"Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP, Society D-TDNotID. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in italian specialist care. J Endocrinol Invest. 2021;44(9):1879\u201389.","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1955_CR33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tem.2011.07.003","volume":"22","author":"G Iacobellis","year":"2011","unstructured":"Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22(11):450\u20137.","journal-title":"Trends Endocrinol Metab"},{"issue":"21","key":"1955_CR34","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","volume":"77","author":"S Kenchaiah","year":"2021","unstructured":"Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, Burke GL, McClelland RL, Arai AE, Bluemke DA. Pericardial Fat and the risk of heart failure. J Am Coll Cardiol. 2021;77(21):2638\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"1955_CR35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2020.04.031","volume":"314","author":"G Milanese","year":"2020","unstructured":"Milanese G, Silva M, Ledda RE, Goldoni M, Nayak S, Bruno L, Rossi E, Maffei E, Cademartiri F, Sverzellati N. Validity of epicardial fat volume as biomarker of coronary artery disease in symptomatic individuals: results from the ALTER-BIO registry. Int J Cardiol. 2020;314:20\u20134.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1955_CR36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12944-017-0475-9","volume":"16","author":"RMS da Silva","year":"2017","unstructured":"da Silva RMS, de Mello RJV. Fat deposition in the left ventricle: descriptive and observacional study in autopsy. Lipids Health Dis. 2017;16(1):86.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"1955_CR37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10554-022-02723-8","volume":"39","author":"X Dong","year":"2023","unstructured":"Dong X, Strudwick M, Wang WY, Borlaug BA, van der Geest RJ, Ng AC, Delgado V, Bax JJ, Ng AC. Impact of body mass index and diabetes on myocardial fat content, interstitial fibrosis and function. Int J Cardiovasc Imaging. 2023;39(2):379\u201390.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"Suppl 2","key":"1955_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2337\/dc11-s250","volume":"34","author":"P Iozzo","year":"2011","unstructured":"Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care. 2011;34(Suppl 2):371\u20139.","journal-title":"Diabetes Care"},{"issue":"1","key":"1955_CR39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-023-01782-y","volume":"22","author":"R Kashiwagi-Takayama","year":"2023","unstructured":"Kashiwagi-Takayama R, Kozawa J, Hosokawa Y, Kato S, Kawata S, Ozawa H, Mineo R, Ishibashi C, Baden MY, Iwamoto R, et al. Myocardial fat accumulation is associated with cardiac dysfunction in patients with type 2 diabetes, especially in elderly or female patients: a retrospective observational study. Cardiovasc Diabetol. 2023;22(1):48.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1955_CR40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mrm.10372","volume":"49","author":"LS Szczepaniak","year":"2003","unstructured":"Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D\u2019Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49(3):417\u201323.","journal-title":"Magn Reson Med"},{"key":"1955_CR41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12968-016-0228-3","volume":"18","author":"PA Liao","year":"2016","unstructured":"Liao PA, Lin G, Tsai SY, Wang CH, Juan YH, Lin YC, Wu MT, Yang LY, Liu MH, Chang TC, et al. Myocardial triglyceride content at 3 T cardiovascular magnetic resonance and left ventricular systolic function: a cross-sectional study in patients hospitalized with acute heart failure. J Cardiovasc Magn Reson. 2016;18:9.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"12","key":"1955_CR42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jacc.2008.04.068","volume":"52","author":"S Hammer","year":"2008","unstructured":"Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, Meinders EA, Romijn JA, de Roos A, Smit JW. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52(12):1006\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1955_CR43","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.amjcard.2009.02.025","volume":"103","author":"AP Viljanen","year":"2009","unstructured":"Viljanen AP, Karmi A, Borra R, Parkka JP, Lepomaki V, Parkkola R, Lautamaki R, Jarvisalo M, Taittonen M, Ronnemaa T, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol. 2009;103(12):1721\u20136.","journal-title":"Am J Cardiol"},{"issue":"15","key":"1955_CR44","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","volume":"119","author":"RW van der Meer","year":"2009","unstructured":"van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119(15):2069\u201377.","journal-title":"Circulation"},{"issue":"1","key":"1955_CR45","doi-asserted-by":"crossref","first-page":"15691","DOI":"10.1038\/ncomms15691","volume":"8","author":"M Ogrodnik","year":"2017","unstructured":"Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8(1):15691.","journal-title":"Nat Commun"},{"issue":"7","key":"1955_CR46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.15252\/embj.201592862","volume":"35","author":"C Correia-Melo","year":"2016","unstructured":"Correia-Melo C, Marques FD, Anderson R, Hewitt G, Hewitt R, Cole J, Carroll BM, Miwa S, Birch J, Merz A, et al. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J. 2016;35(7):724\u201342.","journal-title":"EMBO J"},{"issue":"9","key":"1955_CR47","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/ejhf.1840","volume":"22","author":"Z Dang","year":"2020","unstructured":"Dang Z, Avolio E, Thomas AC, Faulkner A, Beltrami AP, Cervellin C, Carrizzo A, Maciag A, Gu Y, Ciaglia E, et al. Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1\/CXCR4 signalling pathway. Eur J Heart Fail. 2020;22(9):1568\u201381.","journal-title":"Eur J Heart Fail"},{"key":"1955_CR48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","volume":"21","author":"JL Kirkland","year":"2017","unstructured":"Kirkland JL, Tchkonia T. Cellular Senescence: a translational perspective. EBioMedicine. 2017;21:21\u20138.","journal-title":"EBioMedicine"},{"issue":"11","key":"1955_CR49","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1210\/en.2016-1398","volume":"157","author":"L Sylow","year":"2016","unstructured":"Sylow L, Long JZ, Lokurkar IA, Zeng X, Richter EA, Spiegelman BM. The Cancer Drug Dasatinib increases PGC-1alpha in adipose tissue but has adverse Effects on glucose tolerance in obese mice. Endocrinology. 2016;157(11):4184\u201391.","journal-title":"Endocrinology"},{"issue":"3","key":"1955_CR50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00395-009-0071-x","volume":"105","author":"SH Ihm","year":"2010","unstructured":"Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol. 2010;105(3):399\u2013407.","journal-title":"Basic Res Cardiol"},{"issue":"10","key":"1955_CR51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","volume":"92","author":"P La Rosee","year":"2013","unstructured":"La Rosee P, Martiat P, Leitner A, Klag T, Muller MC, Erben P, Schenk T, Saussele S, Hochhaus A. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013;92(10):1345\u201350.","journal-title":"Ann Hematol"},{"issue":"8","key":"1955_CR52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1042\/CS20200220","volume":"134","author":"M Santopaolo","year":"2020","unstructured":"Santopaolo M, Gu Y, Spinetti G, Madeddu P. Bone marrow fat: friend or foe in people with diabetes mellitus? Clin Sci (Lond). 2020;134(8):1031\u201348.","journal-title":"Clin Sci (Lond)"},{"issue":"Suppl 3","key":"1955_CR53","first-page":"23","volume":"8","author":"M Furuhashi","year":"2014","unstructured":"Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol. 2014;8(Suppl 3):23\u201333.","journal-title":"Clin Med Insights Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01955-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:16:49Z","timestamp":1700482609000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01955-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01955-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3024470\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experimental procedures involving human patients were covered by ethical approval from Wales Rec 4 (REC reference number: 14\/WA\/1005) and in compliance with the \u201cDeclaration of Helsinki\u201d principles. Patients gave written informed consent for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Experimental procedures involving mice were approved by the British Home Office (PPL number PP1377882), the University of Bristol, and were compliant with the EU Directive 2010\/63\/EU and principles stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}